Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10356 in Healthy Volunteers
NCT04652297Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of keverprazan in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Incidence, severity, and association of AE, SAE, and adverse events leading to withdrawal, Laboratory assessment: Haematology at Day 19 and 6 more. Status: unknown.
02
Drugs
keverprazan
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04652297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04652297.